Replies to post #245231 on Biotech Values

[DewDiligence]

MGTA—(+48%/AH)—seeks reverse-merger partner:

https://www.globenewswire.com/news-release/2023/02/02/2600963/0/en/Magenta-Therapeutics-to-Explore-Strategic-Alternatives.html

Pursuant to a safety halt of its AML/MDA trial one week ago (#msg-171036181), MGTA has ceased all clinical development and is now a shell company.